Royal Bank Of Canada reaffirmed their outperform rating on shares of ProMetic Life Sciences Inc. (TSE:PLI) in a research report report published on Thursday, StockTargetPrices.com reports.
PLI has been the subject of several other research reports. TD Securities restated a speculative buy rating and set a C$4.50 price target on shares of ProMetic Life Sciences in a report on Wednesday, September 28th. Scotiabank restated an outperform rating and set a C$5.00 price target on shares of ProMetic Life Sciences in a report on Thursday, August 25th. Finally, CIBC lowered their price target on shares of ProMetic Life Sciences from C$5.00 to C$4.85 in a report on Thursday, August 25th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of C$4.84.
ProMetic Life Sciences (TSE:PLI) opened at 3.11 on Thursday. The company’s 50-day moving average is $2.95 and its 200 day moving average is $3.00. The firm’s market cap is $1.88 billion. ProMetic Life Sciences has a one year low of $1.67 and a one year high of $3.62.
About ProMetic Life Sciences
ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.